Newborns can be protected from seasonal flu when their mothers are vaccinated during pregnancy, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers observed a 63 percent reduction in proven influenza illness among infants born to vaccinated mothers while the number of serious respiratory illnesses to both mothers and infants dropped by 36 percent. The study is the first to demonstrate that the inactivated influenza vaccine provides protection to both mother and newborn. The findings were presented during the National Vaccine Advisory Committee meeting in Washington, D.C. on Sept. 17 and will be published in the Oct. 9 issue of the New England Journal of Medicine.
The inactivated influenza vaccine (the flu shot) is not licensed for infants younger than six months. The alternative nasal flu vaccine is not available for children under age 2. The flu shot has been recommended for pregnant women in the U.S. since 1997, although approximately 15 percent of pregnant women are vaccinated each year.
"Even though there is no flu vaccine for these children, our study shows that a newborn's risk of infection can be greatly reduced by vaccinating mom during pregnancy. It's a two for one benefit," said Mark Steinhoff, MD, the study's senior author and professor in the BloombergSchool's Department of International Health. "Infants under six months have the highest rates of hospitalization from influenza among children in the U.S. These admission rates are higher than those for the elderly and other high-risk adult groups."
The study was conducted in Bangladesh in collaboration with researchers from the International Centre for Diarrheal Disease Research (ICDDR,B). Researchers observed 340 mothers and their infants as part of the larger Mother's Gift vaccine evaluation study. The mothers were randomly selected to receive either flu vaccine or pneumococcal vaccine.
"Pregnant woman should be encouraged to be vaccinated for the flu to protect their infants and themselves," said Steinhoff.
Additional authors of the study include K. Zaman, S.E. Arifeen, M. Rahman, R. Raqui, N. Shahid and R.F. Breiman from the International Centre for Diarrheal Disease Research in Bangladesh. E. Wilson is with the Bloomberg School of Public Health and S. B. Omer is with EmoryUniversity.
The research was supported by the Bill & Melinda Gates Foundation, United States Agency for International Development (USAID), the NPVO Research Fund, Wyeth Pharmaceuticals Inc., the Thrasher Research Fund, Aventis Pasteur, ICDDR,B and the Johns Hopkins Bloomberg School of Public Health.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.